Exciting Developments: Everads' Breakthroughs in Eye Treatment
Innovative Advances in Retinal Treatment by Everads
Clinical outcomes have shown promising results regarding the safety and feasibility of the Everads Injector, which is set to transform the treatment landscape for retinal conditions. Everads Therapy, a clinical-stage biotechnology firm focused on suprachoroidal delivery methods, has announced that five significant abstracts will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting.
Overview of the Clinical Findings
The clinical results showcase the effectiveness of the Everads Suprachoroidal Injector, particularly in delivering therapeutics for diseases affecting the back of the eye. This innovative platform is distinct due to its proprietary design, which employs a non-sharp tissue separator. This unique feature allows for safe access to the suprachoroidal space through blunt dissection, facilitating the tangential distribution of drugs towards the target area, including the posterior pole and macular region.
Clinical Data Highlights
"We are thrilled to share our clinical data that affirms the safety, tolerability, and performance of our suprachoroidal injector," stated Moshe Weinstein, Chief Executive Officer of Everads Therapy. "These results are instrumental in supporting our clinical trial applications and highlight the potential for future clinical programs utilizing our cutting-edge delivery system." The extensive data exhibited at ARVO underlines the versatility of Everads' approach across various therapeutic avenues.
About the First-in-Human Study
The company's first-in-human study is an open-label trial assessing the safety and performance of the Everads Injector in patients with diabetic macular edema (DME). Results indicate that the device is safe and easy to use, making it suitable for office-based administration.
Expert Insights on Device Usability
Yoreh Barak, MD, Head of Retina at Rambam Medical Center and Principal Investigator for the trial, remarked, "The data we've gathered reaffirm the efficacy, usability, and tolerability of the Everads Injector. This method enables physicians to deliver medications non-surgically to the suprachoroidal area, resulting in safer and more effective treatment for conditions affecting the posterior segment of the eye."
Details of the Presentations at ARVO 2025
Among the notable presentations set for ARVO 2025 are:
- Ocular Pharmacokinetics and Tolerability of VVN481, a Novel JAK Inhibitor, Following Suprachoroidal Delivery in Rabbits - Presentation on May 4, 8:00–9:45 AM, Poster #A0411
- First-In-Human Results of a Novel Suprachoroidal Delivery Injector - Presentation on May 5, 8:30–10:15 AM, Poster #B0509
- Evaluation in Canines of a Novel Device for Suprachoroidal Drug Delivery - Presentation on May 5, 8:30–10:15 AM, Poster #B0500
- A Novel AAV Gene Therapy Complement Inhibitor: KRIYA-825 Exhibits Dose-Dependent Murine Efficacy and NHP Biodistribution - Presentation on May 8, 8:00–9:45 AM, Poster #A0463
- Minimally-Invasive Suprachoroidal Buckling Using a Novel Injector: Pre-Clinical Evaluation in Human Cadaver Eyes - Oral Presentation on May 8, 3:00–3:15 PM, Ballroom J
The Vision of Everads Therapy
Everads Therapy is on a mission to revolutionize the landscape of retinal disease treatment through its advanced suprachoroidal delivery technology. By addressing the shortcomings of traditional methods, the Everads platform allows for efficient and safe drug distribution within the suprachoroidal space without the need for invasive surgical interventions.
The company is actively collaborating with various partners in gene therapy, cell therapy, and small molecule formulations, further pushing the boundaries of its innovative delivery system.
Originating as a spinoff from DALI Medical Devices, a recognized leader in injectable drug delivery technologies, Everads operates within the esteemed RAD Biomed accelerator. Its foundational technologies are licensed from the laboratory of Professor Y Rotenstreich at Sheba Tel Hashomer Medical Center.
For additional insights and updates about Everads Therapy, please visit their official website and follow them on LinkedIn for the latest news and developments.
Frequently Asked Questions
What is the Everads Injector used for?
The Everads Injector is designed for the suprachoroidal delivery of therapeutics aimed at treating retinal diseases.
What are the main advantages of using the Everads Injector?
The device offers a non-surgical method for delivering drugs to the suprachoroidal space, improving safety and treatment efficacy.
Where will the presentations related to Everads take place?
The presentations will take place at the ARVO 2025 Annual Meeting.
What types of diseases does Everads Therapy focus on?
The company focuses on retinal diseases, particularly those impacting the back of the eye.
How does the Everads platform improve treatment options?
It enables faster and broader distribution of therapeutics, potentially offering more effective treatment modalities compared to traditional methods.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
